A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema.
Phase of Trial: Phase IV
Latest Information Update: 30 Nov 2016
At a glance
- Drugs Aliskiren (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 03 Feb 2011 Planned End Date changed from 1 Oct 2009 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 03 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Aug 2009 Additioal trial location (USA) added as reported by ClinicalTrials.gov